<DOC>
	<DOCNO>NCT01501344</DOCNO>
	<brief_summary>This study determine daily oral intake 200g market yogurt fortify calcium content milk basic protein ( MBP ) 80 mg benefit bone cell activity postmenopausal woman . The efficacy product measure examining variation biochemical marker bone turnover . MBP 80 particular protein contain milk ; add yogurt provide study . The effect MBP 80 quality bone tissue yet prove .</brief_summary>
	<brief_title>Open-label Study Evaluate Effect MBP-80 Bone Remodelling</brief_title>
	<detailed_description>The morbidity mortality associate osteoporotic related fracture devastate term disability individual cost global economy . As world 's population age , present major public health issue since large proportion woman remain undiagnosed untreated even availability therapy calcium vitamin D supplement . Consequently , remain important evaluate dairy product ( milk , cheese , yogurt ) safely provide supplement bone health addition current pharmacological treatment . The rationale study assess beneficial effect daily dietary supplement MBP 80 mg yogurt matrix fortify calcium content bone remodelling healthy early postmenopausal woman neither osteoporosis estrogens/progestin therapy .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<criteria>Early postmenopausal woman , age 4560 yr old inclusive , 15 yr since last menses ; naturally surgically menopausal result bilateral oophorectomy . Hysterectomized ( ≤ 5 yr ) woman 5060 yr old . Lumbar Spine ( L.S . ; L1L4 ) BMD &gt; 0.772 g/cm2 ( Tscore 2.5 Hologic ) , Femoral Neck BMD &gt; 0.572 g/cm2 ( Tscore 2.5 Hologic ) , Total Hip BMD &gt; 0.637 g/cm2 ( Tscore 2.5 Hologic ) . Subjects must sign Ethic Committee approve Informed Consent Form study procedure initiate . Any intake calcium vitamin D supplement include multivitamin , nutritional dietary supplement kind contain calcium vit D within 3 month prior screen visit 1A . Daily dietary calcium intake &gt; 600 mg assess Calcium Intake Calculator ( Appendix E ) . Subjects already suffer osteoporosis basis low BMD Tscore ≤ 2.5 site personal history fragility fracture age 40 . Any past present use : Bisphosphonate PTH PTH derivative , eg . teriparatide Androgens , anabolic steroid testosterone Tibolone Calcitriol Strontium ranelate Lithium , chronic warfarin heparin use &gt; 3 month , anticonvulsant ( benzodiazepine allow ) , gonadotrophinreleasing hormone agonist , glitazones . Administration follow treatment within last 3 month prior screen : Glucocorticosteroids ( &gt; 5 mg prednisone equivalent per day &gt; 10 day ) Systemic hormone replacement therapy Selective estrogen receptor modulators ( SERMs ) , eg , raloxifene Calcitonin Any unapproved hormonelike treatment opinion Principal Investigator ( P.I . ) , i.e . phytoestrogens , isoflavones , etc . Antacids , H2 blocker , proton pump inhibitor &gt; 10 day Iron supplement &gt; 10 day Any condition disease may , accord P.I. , interfere evaluation L.S . Hip BMD ; include limited : advanced scoliosis extensive lumbar fusion , less 2 lumbar vertebra ( L1L4 ) evaluable DXA . Hyper hypothyroidism : patient stable dose thyroid treatment normal TSH allow . Lab value TSH must normal slightly abnormal , though clinically non significant opinion P.I . Current hyper hypoparathyroidism , opinion P.I . Current hypocalcemia , opinion P.I . Vit D insufficiency ( 25OH vitamin D level &lt; 40 nmol/L ) Significantly impaired renal function hereby define estimate GFR ≤ 60 mL/min/ 1.73 m2 ( 4variable MDRD equation ) . Rheumatoid arthritis . Paget 's disease bone . Any history cancer within past 5 year ( except basal cell carcinoma , dermal squamous cell carcinoma 6 month remission cervix carcinoma situ ) . Any bone disease , i.e . osteomalacia osteogenesis imperfecta . Chronic asthma , opinion P.I . Malabsorption syndrome ( coeliac disease , inflammatory bowel disease , gastric bypass ) . Height , weight girth may preclude accurate DXA measurement ; BMI outside range 18.5 35 inclusive . Variation 2 kg ( gain loss ) within 2 month Screening . Presence vertebral fracture screen VFA ( Vertebral Fracture Assessment ) measure DXA . Any previous ongoing clinically significant illness , opinion P.I. , could prevent patient complete study . Evidence alcohol substance abuse within last 12 month P.I . believe would interfere understand complete study . Subject kind disorder compromise ability subject give write informed consent and/or comply study procedure . Subject currently enrol yet complete least 30 day since end investigational device drug trial ( ) , subject receive investigational agent ( ) .</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>osteoporosis</keyword>
	<keyword>postmenopausal woman</keyword>
	<keyword>bone remodelling</keyword>
	<keyword>bone turnover marker</keyword>
</DOC>